SLN Research | Milton Maxwell

SLN

Silence Therapeutics plc

6.27

-0.33-5%

Dec 16, 4:00:01 PM EST

Upcoming Earnings

Report date

≈ -/-

Earnings Call Transcripts

This Quarter (Q4 '25)

No earnings call transcript available yet

Last Quarter (Q3 '25)

No earnings call transcript available

Key Stats

Market Cap

296.16M

P/E (TTM)

Basic EPS (TTM)

-1.35

Dividend Yield

Recent Filings

8-K

CFO Hellums joins Board

12/22/25Dec 22, 2025

Silence Therapeutics appointed CFO Rhonda Hellums to its Board as an executive director on December 18, 2025, effective immediately, with her term expiring at the 2026 AGM. She joins without extra compensation or committee roles. No family ties or conflicts disclosed. Clean addition.

8-K

CEO exits; interim leader named

12/15/25Dec 15, 2025

Silence Therapeutics' CEO Craig Tooman stepped down by mutual consent effective December 14, 2025, after serving since 2022. Chairman Iain Ross steps in as interim principal executive officer; James Ede-Golightly rejoins the board immediately. Separation and compensation terms pending. Leadership shifts while company affirms robust financial and operational health.

10-Q

Q3 FY2025 results

11/6/25Nov 6, 2025

Silence Therapeutics posted Q3 revenue of $0.2M, down sharply y/y from $1.5M amid lighter AstraZeneca collaboration activity, while YTD revenue fell to $0.5M from $18.0M (no milestones vs $10M prior year). R&D costs ticked up 2% q/q to $20.5M on proprietary programs like divesiran Phase 2, driving operating loss to $26.2M (better than $30.0M y/y) and net loss to $21.0M or $(0.15) per share, confirmed vs 142M diluted shares. Cash burned $45.0M in operations (no capex for FCF), leaving $102.2M in cash/short-term investments at September 30, 2025—enough into 2028 with milestones. Restructuring trimmed $1.3M YTD. Cash lasts years. Evolving data privacy laws pose compliance risks.

8-K

SANRECO Phase 2 fully enrolled

11/6/25Nov 6, 2025

Silence Therapeutics fully enrolled its SANRECO Phase 2 trial of divesiran in polycythemia vera, with 48 phlebotomy-dependent patients; topline results due in Q3 2026. Cash hit $102.2 million, funding operations into 2028, while Q3 net loss narrowed to $21.0 million from $35.5 million. Enrollment accelerated fast.

8-K

SANRECO enrollment complete

10/23/25Oct 23, 2025

Silence Therapeutics completed enrollment in the SANRECO Phase 2 study of divesiran, a first-in-class siRNA targeting TMPRSS6 for polycythemia vera, on October 23, 2025. The global trial enrolled 48 phlebotomy-dependent patients to test divesiran's ability to maintain hematocrit below 45% without phlebotomies over weeks 18-36, using dosing every six or 12 weeks. Topline results are expected in Q3 2026. Enrollment wrapped fast.

About

Silence Therapeutics plc, a biotechnology company, engages in the discovery and development of novel molecules incorporating short interfering ribonucleic acid (siRNA) to inhibit the expression of specific target genes in hematology, cardiovascular, and rare diseases. The company develops Zerlasiran (SLN360), which is in Phase II clinical trial for cardiovascular disease associated with elevated lipoprotein(a); Divesiran (SLN124), an siRNA molecule that is in Phase I clinical trial for the treatment of genetic hematological conditions, including polycythemia vera; and SLN548 for complement-mediated disease. Silence Therapeutics plc has collaboration agreements with AstraZeneca PLC to discover, develop, and commercialize siRNA therapeutics for the treatment of cardiovascular, renal, metabolic, and respiratory diseases; and Hansoh Pharmaceutical Group Company Limited to develop siRNAs. The company was formerly known as SR Pharma plc and changed its name to Silence Therapeutics plc in May 2007. Silence Therapeutics plc was incorporated in 1994 and is headquartered in London, the United Kingdom.

CEO

Mr. Craig A. Tooman M.B.A.

IPO

9/8/2020

Website

https://www.silence-therapeutics.com

Employees

116

Sector

Healthcare

Industry

Biotechnology